134 related articles for article (PubMed ID: 7793897)
1. Photosensitivity associated with ciprofloxacin use in adult patients with cystic fibrosis.
Burdge DR; Nakielna EM; Rabin HR
Antimicrob Agents Chemother; 1995 Mar; 39(3):793. PubMed ID: 7793897
[No Abstract] [Full Text] [Related]
2. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis.
Rubio TT
Diagn Microbiol Infect Dis; 1990; 13(2):153-5. PubMed ID: 2114953
[No Abstract] [Full Text] [Related]
3. Photosensitivity due to ambulatory intravenous ceftazidime in cystic fibrosis patient.
Vinks SA; Heijerman HG; de Jonge P; Bakker W
Lancet; 1993 May; 341(8854):1221-2. PubMed ID: 8098116
[No Abstract] [Full Text] [Related]
4. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Jensen T; Pedersen SS; Nielsen CH; Høiby N; Koch C
J Antimicrob Chemother; 1987 Oct; 20(4):585-94. PubMed ID: 3479420
[TBL] [Abstract][Full Text] [Related]
5. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin.
Alfaham M; Holt ME; Goodchild MC
Br Med J (Clin Res Ed); 1987 Sep; 295(6600):699. PubMed ID: 3117310
[No Abstract] [Full Text] [Related]
6. Cystic fibrosis and drug-induced arthropathy.
Jawad AS
Br J Rheumatol; 1989 Apr; 28(2):179-80. PubMed ID: 2706427
[No Abstract] [Full Text] [Related]
7. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
[TBL] [Abstract][Full Text] [Related]
8. Ciprofloxacin in the treatment of Pseudomonas infection in cystic fibrosis patients.
Rubio TT; Shapiro C
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():147-52. PubMed ID: 3100490
[TBL] [Abstract][Full Text] [Related]
9. Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.
Moore GC; Redfern J; Shiach CR; Webb K; Jones AM
J Cyst Fibros; 2007 May; 6(3):209-11. PubMed ID: 17045852
[TBL] [Abstract][Full Text] [Related]
10. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
[TBL] [Abstract][Full Text] [Related]
11. Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
Marchetti F; Candusso M; Faraguna D; Assael BM
Lancet; 2002 Feb; 359(9306):626-7. PubMed ID: 11867141
[No Abstract] [Full Text] [Related]
12. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
LeBel M
Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
[TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin therapy in cystic fibrosis.
Scully BE; Nakatomi M; Ores C; Davidson S; Neu HC
Am J Med; 1987 Apr; 82(4A):196-201. PubMed ID: 3555036
[TBL] [Abstract][Full Text] [Related]
14. Tolerance and safety of ciprofloxacin in paediatric patients.
Black A; Redmond AO; Steen HJ; Oborska IT
J Antimicrob Chemother; 1990 Dec; 26 Suppl F():25-9. PubMed ID: 2292542
[TBL] [Abstract][Full Text] [Related]
15. Ciprofloxacin-induced acute renal failure in a patient with cystic fibrosis.
Bald M; Ratjen F; Nikolaizik W; Wingen AM
Pediatr Infect Dis J; 2001 Mar; 20(3):320-1. PubMed ID: 11303842
[TBL] [Abstract][Full Text] [Related]
16. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis.
Schaad UB; Wedgwood J; Ruedeberg A; Kraemer R; Hampel B
Pediatr Infect Dis J; 1997 Jan; 16(1):106-11; discussion 123-6. PubMed ID: 9002119
[TBL] [Abstract][Full Text] [Related]
17. Ciprofloxacin therapy in cystic fibrosis.
Raeburn JA; Govan JR; McCrae WM; Greening AP; Collier PS; Hodson ME; Goodchild MC
J Antimicrob Chemother; 1987 Sep; 20(3):295-6. PubMed ID: 3680073
[No Abstract] [Full Text] [Related]
18. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin.
Schaad UB; Stoupis C; Wedgwood J; Tschaeppeler H; Vock P
Pediatr Infect Dis J; 1991 Oct; 10(10):723-9. PubMed ID: 1945573
[TBL] [Abstract][Full Text] [Related]
19. If you can't stand the rash, get out of the kitchen: an unusual adverse reaction to ciprofloxacin.
Jaffé A; Bush A
Pediatr Pulmonol; 1999 Dec; 28(6):449-50. PubMed ID: 10587421
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pharmacokinetic aspects of ciprofloxacin in the treatment of acute exacerbations of pseudomonas infection in cystic fibrosis patients.
Steen HJ; Scott EM; Stevenson MI; Black AE; Redmond AO; Collier PS
J Antimicrob Chemother; 1989 Nov; 24(5):787-95. PubMed ID: 2599998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
